市場調查報告書

唐氏症:流行病學預測 (∼2030年)

Down Syndrome - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 968107
出版日期 內容資訊 英文 94 Pages
商品交期: 最快1-2個工作天內
價格
唐氏症:流行病學預測 (∼2030年) Down Syndrome - Epidemiology Forecast to 2030
出版日期: 2020年10月30日內容資訊: 英文 94 Pages
簡介

本報告提供美國,歐洲5個國家(德國,西班牙,義大利,法國,英國)以及日本的7個主要市場上唐氏症市場相關說明,提供疾病的背景和概要,各國流行病學等相關資訊。

目錄

第1章 主要考察

第2章 唐氏症:流行病學概要

  • 2017年:唐氏症的患者佔有率(%)分佈
  • 2030年:唐氏症的患者佔有率(%)分佈

第3章 摘要整理

第4章 組織

第5章 唐氏症:疾病概要

  • 簡介
  • 症狀
  • 唐氏症的種類
  • 唐氏症的危險因素
  • 唐氏症的遺傳的根據
    • 基因表現變異
  • 病因
    • 唐氏症的表現型的變動性
    • 唐氏症的代謝的不平衡
  • 唐氏症相關的臨床症狀
  • 唐氏症的診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的唐氏症的患病人口的總合

第7章 主要7個國家的唐氏症的流行病學

  • 前提條件與理論的根據
  • 美國
  • 美國的唐氏症患病者的總合
  • 美國的唐氏症患病者:性別
  • 美國的唐氏症患病者:各類型
  • 美國的唐氏症患病者:各年齡
  • 美國的唐氏症患病者:各臨床症狀
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 附錄

  • 報告的調查手法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

目錄
Product Code: DIEI0364

DelveInsight's 'Down syndrome (DS) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Down syndrome, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Down syndrome (DS) Disease Understanding

Down syndrome (DS) is a congenital disability with substantial medical and social costs caused by trisomy of whole or part of chromosome 21. It is the most prevalent genetic disease worldwide and the common genetic cause of intellectual disabilities. Generally, there are three cytogenetic forms of Down syndrome: free trisomy 21, mosaic trisomy 21, and Robertsonian translocation trisomy 21.

Regardless of the type of Down syndrome a person may have a critical portion of chromosome 21 present in all or some of their cells. This additional genetic material alters the course of development and causes the characteristics associated with Down syndrome.

Delayed development and behavioral problems are often reported in children with Down syndrome. Affected individuals can have growth problems, which might affect their speech and language development later and more slowly than. Behavioral issues can include attention problems, obsessive/compulsive behavior, and stubbornness, or tantrums. A small percentage of people with Down syndrome may also be diagnosed with developmental conditions called autism spectrum disorders, which affect communication and social interaction.

The cause of the extra full or partial chromosome is still unknown. Maternal age is the only factor that has been linked to an increased chance of having a baby with Down syndrome resulting from nondisjunction or mosaicism. Prenatal and postnatal testing has become commonly used to diagnose different cases presenting the same pathology. Early clinical diagnosis is vital for patient prognosis.

Down syndrome (DS) Epidemiology

The Down syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Down syndrome epidemiology segmented as the total diagnosed prevalent cases of Down syndrome, type-specific diagnosed prevalent population of Down syndrome, gender-specific diagnosed prevalent population of down syndrome, age-specific diagnosed prevalent population of Down syndrome and diagnosed prevalent population of down syndrome by clinical manifestation. The report includes the Prevalent scenario of Down syndrome symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Down Syndrome (DS) Epidemiology

The epidemiology segment also provides the Down syndrome (DS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent population of Down Syndrome Associated in the 7MM countries estimated to be 699,750 cases in 2017.

  • As per the estimates, the United States has the highest prevalent population of Down syndrome with 295,492 cases in 2017.
  • Among the EU5 countries, Germany had the highest prevalent population of 56,529 cases, followed by France.

Scope of the Report:

  • Down syndrome (DS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Down syndrome (DS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Down syndrome (DS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Down syndrome (DS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Down syndrome
  • The report provides the segmentation of the Down syndrome (DS) epidemiology by Prevalent Cases of Down syndrome (DS) in the 7MM
  • The report provides the segmentation of the Down syndrome (DS) epidemiology by Gender-specific Prevalent Cases of Down syndrome (DS) in 7MM
  • The report provides the segmentation of the Down syndrome (DS) epidemiology by Age-specific Prevalent Cases of Down syndrome (DS) in 7MM
  • The report provides the segmentation of the Down syndrome (DS) epidemiology by Type-specific Prevalent Cases of Down syndrome (DS) in 7MM
  • The report provides the segmentation of the Down syndrome (DS) epidemiology by Site-specific Prevalent Cases of Down syndrome (DS) in 7MM

Report Highlights:

  • 11-year Forecast of Down syndrome (DS) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Down syndrome (DS)
  • Prevalent Cases according to segmentation: Gender-specific Prevalence of Down syndrome (DS)
  • Prevalent Cases according to segmentation: Age-specific Prevalence of Down syndrome (DS)

KOL- Views

DelveInsight interviews KOLs and obtain SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population with Down syndrome (DS)?
  • What are the key findings of the Down syndrome (DS) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of Down syndrome (DS) patients across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow by in the 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of Down syndrome?
  • What are the currently available treatments for Down syndrome?

Reasons to buy:

The Down syndrome (DS) Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Down syndrome (DS) market
  • Quantify patient populations in the global Down syndrome (DS) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Down syndrome (DS) therapeutics in each of the markets covered
  • Understand the magnitude of Down syndrome (DS) population by its prevalence
  • Understand the magnitude of Down syndrome (DS) population by its Gender-specific cases
  • Understand the magnitude of Down syndrome (DS) population by its Age-specific cases
  • The Down syndrome (DS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Down syndrome (DS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

In the US, DS birth prevalence was estimated by de Graaf et al. (n.d.) at 12.6/10,000 (or 1 in 792) as of 2010. However, only a few studies have estimated US population prevalence. Two previous US studies targeted the age group 0-19 years. For this age group, Shin et al. (n.d.) estimated the population prevalence of 10.3/ 10,000 (or 1 in 971) as of 2002. Besser et al. (n.d.) estimated the prevalence at 8.3/10,000 (or 1 in 1,205) as of 2003.

Table of Contents

1. Key Insights

2. Down syndrome: Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Down syndrome in 2017
  • 2.2. Patient Share (%) Distribution of Down syndrome in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Down syndrome

  • 5.1. Introduction
  • 5.2. Symptoms
  • 5.3. Types of Down syndrome
  • 5.4. Risk factors for Down syndrome
  • 5.5. Genetic Basis of Down syndrome
    • 5.5.1. Gene expression variation
  • 5.6. Etiopathogenesis
    • 5.6.1. Phenotypic Variability of Down syndrome
    • 5.6.2. Metabolic Imbalance in Down syndrome
  • 5.7. Clinical Conditions Associated with Down syndrome
  • 5.8. Diagnosis of Down syndrome

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Total Diagnosed Prevalent Population of Down syndrome in the 7MM

7. Epidemiology of Down syndrome in the 7MM

  • 7.1. Assumptions and Rationale
  • 7.2. United States
  • 7.3. Total Diagnosed Prevalent Cases of Down syndrome in the US
  • 7.4. Gender-specific cases of Down syndrome in the US
  • 7.5. Type-specific cases of Down syndrome in the US
  • 7.6. Age-specific cases of Down syndrome in the US
  • 7.7. Diagnosed cases of Down syndrome by Clinical Manifestations in the US
  • 7.8. Germany
    • 7.8.1. Total Diagnosed Prevalent Cases of Down syndrome in Germany
    • 7.8.2. Gender-specific cases of Down syndrome in Germany
    • 7.8.3. Type-specific cases of Down syndrome in Germany
    • 7.8.4. Age-specific cases of Down syndrome in Germany
    • 7.8.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Germany
  • 7.9. France
    • 7.9.1. Total Diagnosed Prevalent Cases of Down syndrome in France
    • 7.9.2. Gender-specific cases of Down syndrome in France
    • 7.9.3. Type-specific cases of Down syndrome in France
    • 7.9.4. Age-specific cases of Down syndrome in France
    • 7.9.5. Diagnosed cases of Down syndrome by Clinical Manifestation in France
  • 7.10. Italy
    • 7.10.1. Total Diagnosed Prevalent Cases of Down syndrome in Italy
    • 7.10.2. Gender-specific cases of Down syndrome in Italy
    • 7.10.3. Type-specific cases of Down syndrome in Italy
    • 7.10.4. Age-specific cases of Down syndrome in Italy
    • 7.10.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Italy
  • 7.11. Spain
    • 7.11.1. Total Diagnosed Prevalent Cases of Down syndrome in Spain
    • 7.11.2. Gender-specific cases of Down syndrome in Spain
    • 7.11.3. Type-specific cases of Down syndrome in Spain
    • 7.11.4. Age-specific cases of Down syndrome in Spain
    • 7.11.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Spain
  • 7.12. The UK
    • 7.12.1. Total Diagnosed Prevalent Cases of Down syndrome in the UK
    • 7.12.2. Gender-specific cases of Down syndrome in the UK
    • 7.12.3. Type-specific cases of Down syndrome in the UK
    • 7.12.4. Age-specific cases of Down syndrome in the UK
    • 7.12.5. Diagnosed cases of Down syndrome by Clinical Manifestation in the UK
  • 7.13. Japan
    • 7.13.1. Total Diagnosed Prevalent Cases of Down syndrome in Japan
    • 7.13.2. Gender-specific cases of Down syndrome in Japan
    • 7.13.3. Type-specific cases of Down syndrome in Japan
    • 7.13.4. Age-specific cases of Down syndrome in Japan
    • 7.13.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Japan

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1: Candidate dosage-sensitive genes on chromosome 21causing DS phenotype
  • Table 2: Common techniques used for the diagnosis of Down's syndrome along with its advantages and disadvantages
  • Table 3: Total Prevalent Patient Population of Down syndrome in 7MM (2017-2030)
  • Table 4: Total Diagnosed Prevalent Cases of Down syndrome in the US (2017-2030)
  • Table 5: Gender-specific cases of Down syndrome in the US (2017-2030)
  • Table 6: Type-specific cases of Down syndrome in the US (2017-2030)
  • Table 7: Age-specific cases of Down syndrome in the US (2017-2030)
  • Table 8: Diagnosed cases of Down syndrome by Clinical Manifestation in the US (2017-2030)
  • Table 9: Total Diagnosed Prevalent Cases of Down syndrome in Germany (2017-2030)
  • Table 10: Gender-specific cases of Down syndrome in Germany (2017-2030)
  • Table 11: Type-specific cases of Down syndrome in Germany (2017-2030)
  • Table 12: Age-specific cases of Down syndrome in Germany (2017-2030)
  • Table 13: Diagnosed cases of Down syndrome by Clinical Manifestation in Germany (2017-2030)
  • Table 14: Total Diagnosed Prevalent Cases of Down syndrome in France (2017-2030)
  • Table 15: Gender-specific cases of Down syndrome in France (2017-2030)
  • Table 16: Type-specific cases of Down syndrome in France (2017-2030)
  • Table 17: Age-specific cases of Down syndrome in France (2017-2030)
  • Table 18: Diagnosed cases of Down syndrome by Clinical Manifestation in France (2017-2030)
  • Table 19: Total Diagnosed Prevalent Cases of Down syndrome in Italy (2017-2030)
  • Table 20: Gender-specific cases of Down syndrome in Italy (2017-2030)
  • Table 21: Type-specific cases of Down syndrome in Italy (2017-2030)
  • Table 22: Age-specific cases of Down syndrome in Italy (2017-2030)
  • Table 23: Diagnosed cases of Down syndrome by Clinical Manifestation in Italy (2017-2030)
  • Table 24: Total Diagnosed Prevalent Cases of Down syndrome in Spain (2017-2030)
  • Table 25: Gender-specific cases of Down syndrome in Spain (2017-2030)
  • Table 26: Type-specific cases of Down syndrome in Spain (2017-2030)
  • Table 27: Age-specific cases of Down syndrome in Spain (2017-2030)
  • Table 28: Diagnosed cases of Down syndrome by Clinical Manifestation in Spain (2017-2030)
  • Table 29: Total Diagnosed Prevalent Cases of Down syndrome in the UK (2017-2030)
  • Table 30: Gender-specific cases of Down syndrome in the UK (2017-2030)
  • Table 31: Type-specific cases of Down syndrome in the UK (2017-2030)
  • Table 32: Age-specific cases of Down syndrome in the UK (2017-2030)
  • Table 33: Diagnosed cases of Down syndrome by Clinical Manifestation in the UK (2017-2030)
  • Table 34: Total Diagnosed Prevalent Cases of Down syndrome in Japan (2017-2030)
  • Table 35: Gender-specific cases of Down syndrome in Japan (2017-2030)
  • Table 36: Type-specific cases of Down syndrome in Japan (2017-2030)
  • Table 37: Age-specific cases of Down syndrome in Japan (2017-2030)
  • Table 38: Diagnosed cases of Down syndrome by Clinical Manifestation in Japan (2017-2030)

List of Figures

  • Figure 1: Physical Symptoms
  • Figure 2: Developmental and Behavioral Symptoms
  • Figure 3: Types of Down syndrome
  • Figure 4: Comparison of balanced translocation and translocation DS Karyotype
  • Figure 5: Risk Factors for Down syndrome
  • Figure 6: Clinical conditions associated with Down syndrome
  • Figure 7: Karyotyping for diagnosis of Down syndrome
  • Figure 8: Total Prevalent Patient Population of Down syndrome in 7MM (2017-2030)
  • Figure 9: Total Diagnosed Prevalence of Down syndrome in the US (2017-2030)
  • Figure 10: Gender-specific cases of Down syndrome in the US (2017-2030)
  • Figure 11: Type-specific cases of Down syndrome in the US (2017-2030)
  • Figure 12: Age-specific cases of Down syndrome in the US (2017-2030)
  • Figure 13: Diagnosed cases of Down syndrome by Clinical Manifestation in the US (2017-2030)
  • Figure 14: Total Diagnosed Prevalence of Down syndrome in Germany (2017-2030)
  • Figure 15: Gender-specific cases of Down syndrome in Germany (2017-2030)
  • Figure 16: Type-specific cases of Down syndrome in Germany (2017-2030)
  • Figure 17: Age-specific cases of Down syndrome in Germany (2017-2030)
  • Figure 18: Diagnosed cases of Down syndrome by Clinical Manifestation in Germany (2017-2030)
  • Figure 19: Total Diagnosed Prevalence of Down syndrome in France (2017-2030)
  • Figure 20: Gender-specific cases of Down syndrome in France (2017-2030)
  • Figure 21: Type-specific cases of Down syndrome in France (2017-2030)
  • Figure 22: Age-specific cases of Down syndrome in France (2017-2030)
  • Figure 23: Diagnosed cases of Down syndrome by Clinical Manifestation in France (2017-2030)
  • Figure 24: Total Diagnosed Prevalence of Down syndrome in Italy (2017-2030)
  • Figure 25: Gender-specific cases of Down syndrome in Italy (2017-2030)
  • Figure 26: Type-specific cases of Down syndrome in Italy (2017-2030)
  • Figure 27: Age-specific cases of Down syndrome in Italy (2017-2030)
  • Figure 28: Diagnosed cases of Down syndrome by Clinical Manifestation in Italy (2017-2030)
  • Figure 29: Total Diagnosed Prevalence of Down syndrome in Spain (2017-2030)
  • Figure 30: Gender-specific cases of Down syndrome in Spain (2017-2030)
  • Figure 31: Type-specific cases of Down syndrome in Spain (2017-2030)
  • Figure 32: Age-specific cases of Down syndrome in Spain (2017-2030)
  • Figure 33: Diagnosed cases of Down syndrome by Clinical Manifestation in Spain (2017-2030)
  • Figure 34: Total Diagnosed Prevalence of Down syndrome in the UK (2017-2030)
  • Figure 35: Gender-specific cases of Down syndrome in the UK (2017-2030)
  • Figure 36: Type-specific cases of Down syndrome in the UK (2017-2030)
  • Figure 37: Age-specific cases of Down syndrome in the UK (2017-2030)
  • Figure 38: Diagnosed cases of Down syndrome by Clinical Manifestation in the UK (2017-2030)
  • Figure 39: Total Diagnosed Prevalence of Down syndrome in Japan (2017-2030)
  • Figure 40: Gender-specific cases of Down syndrome in Japan (2017-2030)
  • Figure 41: Type-specific cases of Down syndrome in Japan (2017-2030)
  • Figure 42: Age-specific cases of Down syndrome in Japan (2017-2030)
  • Figure 43: Diagnosed cases of Down syndrome by Clinical Manifestation in Japan (2017-2030)